Neostigmine basics

What it is (core concept)

• Neostigmine is an acetylcholinesterase inhibitor used to reverse non-depolarising neuromuscular blockade (e.g., rocuronium, vecuronium, atracurium).
• It increases acetylcholine at the neuromuscular junction so acetylcholine can outcompete the relaxant at nicotinic receptors.
• It also increases acetylcholine at muscarinic receptors (heart, airways, gut) → unwanted side effects unless an antimuscarinic is co-administered.

When to use it (typical scenarios)

• At the end of surgery when you want to reverse residual paralysis from a non-depolarising muscle relaxant.
• Most appropriate when there is evidence of partial recovery (e.g., TOF count 4 with fade, or TOF ratio still <0.9).
• If there is minimal/no spontaneous recovery (deep block), neostigmine may be ineffective or slow; consider waiting for recovery or using sugammadex for aminosteroid relaxants if appropriate and available.

When NOT to rely on neostigmine

• Deep neuromuscular block (e.g., post-tetanic count only, or TOF count 0–1): neostigmine may not achieve timely/complete reversal.
• As a substitute for neuromuscular monitoring: always use objective monitoring where possible.
• To treat airway obstruction or hypoventilation in PACU without confirming residual neuromuscular blockade—assess and manage ABCs first.

Dosing (practical starter approach)

• Common adult dose range: 0.02–0.07 mg/kg IV (i.e., 20–70 micrograms/kg), guided by depth of block and local policy.
• Typical ‘routine’ dose often used for moderate residual block: ~0.04–0.05 mg/kg IV (check departmental practice).
• Maximum commonly quoted dose: 5 mg total (beyond this, benefit plateaus and side effects increase).
• Give with an antimuscarinic: glycopyrrolate (commonly) or atropine, to reduce bradycardia/bronchospasm/secretions.

Antimuscarinic pairing (why and how)

• Neostigmine increases muscarinic activity → bradycardia, bronchospasm, salivation, increased gut motility.
• Glycopyrrolate is commonly paired (less CNS penetration; tends to give smoother heart rate control).
• Many departments use a fixed ratio mixture or give separately; ensure both drugs are drawn up and administered together (or antimuscarinic just before) to avoid marked bradycardia.

Onset, peak, and what to expect

• Onset is not immediate; expect several minutes for meaningful improvement (often ~5–10 minutes depending on depth of block).
• Reversal is faster and more reliable when some spontaneous recovery is already present.
• Do not extubate purely because you have given neostigmine—confirm recovery clinically and (ideally) with objective TOF ratio ≥0.9.

Monitoring and extubation readiness

• Use quantitative neuromuscular monitoring if available (acceleromyography/electromyography). Aim for TOF ratio ≥0.9 before extubation.
• Clinical tests (head lift, hand grip) are unreliable for excluding residual paralysis—use them as supportive, not definitive, signs.
• Check ventilation (tidal volumes, ETCO2), airway reflexes, and overall anaesthetic depth/analgesia before extubation.

Side effects (what you might see)

• Cardiac: bradycardia, conduction block, rarely severe bradyarrhythmia—risk higher if antimuscarinic omitted or delayed.
• Respiratory: bronchospasm, increased secretions (important in reactive airways).
• GI/GU: increased gut motility, nausea, abdominal cramping; may increase bladder tone.
• Paradoxical weakness can occur if given when already fully recovered (cholinergic excess at the neuromuscular junction).

Practical steps for a safe ‘first time’

• Confirm which relaxant was used and when the last dose was given; check TOF/neuromuscular monitor early (don’t wait until drapes are off).
• Decide if neostigmine is appropriate based on depth of block; if deep block, plan to wait or use an alternative strategy per local policy.
• Draw up neostigmine and antimuscarinic, label clearly, and have resuscitation drugs available (e.g., atropine) in case of bradycardia.
• After giving reversal, allow time, reassess TOF ratio, ventilation, and clinical signs; only then proceed to extubation.